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Once-Daily Dosing of Gentamicin
Gentamicin remains one of the most effective and commonly used antimicrobials
in the armamentarium of clinicians treating pelvic infections. It continues to reli-
ably cover the aerobic gram-negative rods seen within polymicrobial infections.
Available in its generic form, it becomes the low-cost drug of choice in these
settings. So why mess with success?
As Wiesenfield et al point out in this issue of the Journal, you can and should
teach an old dog new tricks. The bactericidal activity of gentamicin is character-
ized by concentration-dependent killing. The higher the drug concentration, the
greater the rate and extent of bactericidal activity. More over, prolonged postan-
tibiotic effects (PAE) are observed in gram-negative bacilli following exposure to
antimicrobials that are inhibitors of protein synthesis, such as gentamicin. PAE
refers to the persistent suppression of bacterial growth following exposure to an
antimicrobial. This PAE is further prolonged, almost doubled in fact, by the pres-
ence of leukocytes.
In clinical trials correlating pharmacokinetic/pharmacodynamic parameters of
aminoglycosides with therapeutic efficacy, a clinical response of > 90% required
the peak level to exceed the minimum inhibition concentration (MIC) by eight-
fold to 10-fold. Once-daily dosing with aminoglycosides is designed to enhance
peak serum concentrations. Peak concentrations that are eight to 10 times higher
than the MIC can reduce the rate of emergence of aminoglycoside-resistant mu-
tants during therapy. In addition, initial exposure of bacteria to aminoglycosides
downregulates subsequent uptake of the drug. During this downregulation, de-
creased killing of bacteria and higher MICs are noted. Once-daily dosing allows
time for this effect to dissipate between doses,e
Finally, once-daily dosing has the potential to reduce the incidence of neph-
rotoxicity and ototoxicity associated with the use of aminoglycosides. Uptake of
these drugs into the renal tubular cells and endolymph of the ear is more efficient
with low sustained concentrations than with high intermittent levels. It also ap-
pears that toxicity is delayed in those patients dosed once a day. Given the typical
short-term, commando-type use of gentamicin in the treatment of pelvic infec-
tions, one could use the agent, expect a response, and discontinue therapy
promptly with less concern for toxicity. Measuring aminoglycoside levels is not
necessary in most of the patients we treat, allowing for additional cost savings.
Gentamicin use in the combination therapy for pelvic infections has a solid
track record of efficacy. Once-daily gentamicin dosing would appear to have an
edge in an environment of cost consciousness and safety.
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